Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions

Core Insights - New analysis confirms that aprocitentan significantly reduces blood pressure and albuminuria in patients with true resistant hypertension and high cardiovascular risk, including those with chronic kidney disease [1][3] Company Overview - Idorsia Ltd is set to present new findings from the Phase 3 PRECISION study of aprocitentan at the American Society of Nephrology Kidney Week 2025 in Houston, TX, from November 5 to 9, 2025 [2] - Aprocitentan is a once-daily, orally active dual endothelin receptor antagonist, approved as TRYVIO in the US for systemic hypertension treatment in combination with other antihypertensives since October 2024 [5] - The drug is also approved as JERAYGO for resistant hypertension treatment in the European Union, UK, and Switzerland, with a marketing authorization application under review in Canada [5] Clinical Findings - A poster presentation titled "Is Aprocitentan's Effect on Albuminuria Merely Due to Lowered BP? Subgroup Analysis of the PRECISION Trial" will take place on November 6, highlighting significant reductions in systolic blood pressure and Urine Albumin-to-Creatinine Ratio (UACR) compared to placebo across all subgroups [3] - The analysis indicates that the reductions in UACR are not solely due to lowered blood pressure, suggesting additional renal-protective mechanisms of aprocitentan, such as decreased glomerular permeability and functional tubular changes [3] Upcoming Events - Idorsia will also participate in the American Heart Association Scientific Sessions 2025 in New Orleans, LA, from November 7 to 10, with a symposium discussing the next era in hypertension treatment [4]